Oral anticoagulation in chronic kidney disease with atrial fibrillation

Abstract

Chronic kidney disease (CKD) and atrial fibrillation (AF) frequently coexist, amplifying the risk of cardiovascular events and mortality. In patients with CKD stage 3 and non-valvular AF, direct oral anticoagulants (DOACs) have shown, compared to vitamin K antagonists (VKA), equal or greater efficacy in the prevention of stroke and systemic embolism, and greater safety. There are no randomizedtrials of the efficacy and safety of DOACs and VKA in advanced CKD. On the other hand, observational studies suggest that DOACs, compared to warfarin, are associated with a lower risk of acute kidney damage and generation/progression of CKD. This paper reviews the epidemiological and pathophysiological aspects of the CKD and AF association, the evidence of the efficacy and safety of warfarin and ACODs in various stages of CKD with AF as well as the comparison between warfarin and ACODs in efficacy and anticoagulant safety, and in its renal effects.

Keywords: Antagonistas de vitamina K; Anticoagulant-related nephropathy; Anticoagulantes orales de acción directa; Atrial fibrillation; Chronic kidney disease; Direct-Acting oral anticoagulants; Enfermedad renal crónica; Fibrilación auricular; Nefropatía por anticoagulantes; Vitamin K antagonist.